GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.79 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.690B Est
GSK (NYSE:GSK) affirms FY2026 Adj EPS guidance from $4.90-$5.00 to $4.90-$5.00 vs $4.79 analyst estimate. Affirms FY2026 sales outlook from $44.754 billion to $44.754 billion vs $45.690 billion estimate.
GSK says it will make $4.90–$5.00 per share next year, which is better than what Wall Street guessed ($4.79). But the company expects lower total sales than experts thought, so there's both good and tricky news mixed together.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.